stockportfolio.pro
Stocks / AVTX vs NNNN
AVTX vs NNNN
Avalo Therapeutics, Inc. and Anbio Biotechnology side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Avalo Therapeutics, Inc. (AVTX) | Anbio Biotechnology (NNNN) | |
|---|---|---|
| Market cap | $0.7B | $0.7B |
| Revenue (latest FY) | $59,000 | $8.65M |
| Net income (latest FY) | $-78.26M | $6.40M |
| Revenue growth (5y CAGR) | -61.2% | -28.4% |
| Net margin | -132642.4% | 74.1% |
| Return on equity | -94.2% | 21.2% |
| P/E ratio | — | 107.4 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 4 |
| Positive free cash flow | — | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AVTX — free Open NNNN — freeFrequently asked questions
Which is bigger, AVTX or NNNN?
Avalo Therapeutics, Inc. is larger by market capitalization — $0.7B versus $0.7B.
Which grows faster, AVTX or NNNN?
Over the last five fiscal years, Anbio Biotechnology grew revenue faster — -28.4%/yr versus -61.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.